MabCure, Inc.

As of December 31, 2011, MabCure, Inc. carries a market capitalization of 4.37M, placing it among publicly traded companies globally. Its enterprise value stands at 4.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2011, MabCure, Inc. has 62.40M shares outstanding.

These figures are as of December 31, 2011. The price-to-sales ratio is 8.81, and the price-to-book ratio stands at 1.13.

These figures are as of December 31, 2011. The EV/Sales ratio of 8.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.48M versus a market cap of 4.37M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2011, MabCure, Inc. maintains a current ratio of 0.17, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.74, indicating elevated leverage, while an interest coverage ratio of -64.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2011, MabCure, Inc. posted a negative return on equity (ROE) of -125.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -116.70, reflecting losses generated across the asset base. The company generates approximately 133,333.33 in revenue per employee across its workforce of 3.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2011, MabCure, Inc. generated 500,000.00 in revenue and converted that into -12.26M in net income, yielding earnings per share of -0.19. EBITDA reached -12.08M, while operating income came in at -708,917.00.

As of December 31, 2011, MabCure, Inc. holds 146,436.00 in cash and equivalents against 261,164.00 in total debt, resulting in a net debt position of 105,637.00. Total book value stands at 3.88M, with working capital of -775,939.00 providing operational flexibility.

MabCure, Inc. produced -61,387.00 in operating cash flow over the twelve months ended December 31, 2011. After subtracting - - in capital expenditures, free cash flow totaled -61,387.00 - equivalent to 0.00 per share.

Over the twelve months ended December 31, 2011, MabCure, Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -141.78 and net profit margin of -2,452.80 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2011. Free cash flow yield is negative at -1.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.82, meaning MabCure, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MabCure, Inc.'s most recent stock split took place on November 26, 2007 with a 1:20 split ratio.

As of December 31, 2011, MabCure, Inc. has an Altman Z-Score of -115.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.